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Abstract
The bromodomain and extra terminal (BET) family protein bromodomain con-
taining protein 4 (BRD4) is an epigenetic regulator recently identified as a ther-
apeutic target for several hematological cancers, notably mixed lineage
leukemia-fusion acute myeloid leukemia (MLL-AML). Here, we show that the
BRD4 bromodomain inhibitor JQ1 is highly active against the p53-wild-type
Ontario Cancer Institute (OCI)-AML3 cell line which carries mutations in
nucleophosmin (NPM1) and DNA methyltransferase 3 (DNMT3A) genes com-
monly associated with poor prognostic disease. We find that JQ1 causes caspase
3/7-mediated apoptosis and DNA damage response in these cells. In combina-
tion studies, we show that histone deacetylase (HDAC) inhibitors, the HDM2
inhibitor Nutlin-3, and the anthracycline daunorubicin all enhance the apopto-
tic response of JQ1. These compounds all induce activation of p53 suggesting
that JQ1 might sensitize AML cells to p53-mediated cell death. In further
experiments, we show that BRD4 associates with acetylated p53 but that this
association is not inhibited by JQ1 indicating that the protein–protein interac-
tion does not involve bromodomain binding of acetylated lysines. Instead, we
propose that JQ1 acts to prevent BRD4-mediated recruitment of p53 to chro-
matin targets following its activation in OCI-AML3 cells resulting in cell cycle
arrest and apoptosis in a c-MYC-independent manner. Our data suggest that
BET bromodomain inhibition might enhance current chemotherapy strategies
in AML, notably in poor-risk DNMT3A/NPM1-mutated disease.
Introduction
Several recent papers have demonstrated the therapeutic
potential of targeted inhibition of bromodomain-
containing proteins in certain hematological malignancies
including acute myeloid leukemia (AML) [1, 2] and mul-
tiple myeloma (MM) [3, 4]. The target proteins belong to
the bromodomain and extra terminal (BET) family of
adaptors (BRD2, BRD3, BRD4, and BRDT), which con-
tain acetyl-lysine recognition motifs, or bromodomains,
that “read” posttranslational acetylation modifications of
chromatin [5, 6] and other proteins modified by acetyla-
tion such as nuclear factor kappa light chain enhancer of
activated b cells (NFjB) [7].
BRD4 in particular has been identified as a key therapeu-
tic target in AML based on an RNAi screen of epigenetic
genes in an mixed lineage leukemia (MLL) fusion leukemia
mouse model [1]. The bromodomains of the BET family
proteins bind acetylated lysine residues present in histone
tails that are typically associated with an open chromatin
state and transcriptional activation [8]. Small molecule
inhibitors of the bromodomain pocket, such as JQ1 and
I-BET, disrupt bromodomain containing protein 4 (BRD4)
recruitment to chromatin leading to downregulation of key
oncogenes, notably cellular-myelocytomatosis oncogene
(c-MYC) [1, 3, 4], BCL2, and CDK6 [2]. This results in
reactivation of the p21 tumor suppressor [4] leading to
cell cycle arrest and apoptosis of many, but not all,
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hematological cell lines and malignant primary cells, partic-
ularly those with MLL gene rearrangements. JQ1 interferes
with the ability of BRD4 to “read” acetylated histones that
facilitate transcriptional activation.
Although the effects of BRD4 inhibition are at least
partially due to its role in sustaining c-MYC expression,
the downregulation of c-MYC induced by JQ1 is not
sufficient to cause apoptosis as c-MYC downregulation
has been observed in cell lines that are poorly responsive
to JQ1 such as K562 cells [1]. Furthermore, ectopic
c-MYC expression is unable to prevent JQ1-induced cell
death but can overcome cell cycle arrest and differentia-
tion induced by this compound [1].
To our knowledge, this study is the first to show that
JQ1 is active against the Ontario Cancer Institute (OCI)-
AML3 cell line which carries mutations of the nucleophos-
min (NPM1) and DNA methyltransferase 3 (DNMT3A)
genes that are highly recurrent in AML and commonly
associated with poor risk disease. Beyond this, the princi-
pal aim of the study was to explore the broader therapeutic
potential of BET bromodomain inhibitors by identifying
synergistic interactions with other compounds and to
probe the mechanism of JQ1 action. We show that com-
bined treatment with other compounds known to activate
p53, namely histone deacetylase (HDAC) inhibitors,
Nutlin-3 and daunorubicin, all potentiate the action of
JQ1 on OCI-AML3 cells suggesting JQ1-induced cell death
is via a p53-mediated pathway that appears to involve a
caspase 3/7-dependent mechanism. Furthermore, we show
that BRD4 associates with activated p53 suggesting that
BRD4 inhibition by JQ1 may result in failed recruitment
of p53 to chromatin leading to impaired DNA damage
repair response, cell cycle arrest, and cell death.
Material and Methods
Reagents
Vorinostat was from Stratatech (Suffolk, U.K.), Nutlin-3,
trichostatin A and sodium butyrate were obtained from
Sigma (Poole, U.K.); penicillin, streptomycin, L-glutamine
and RPMI 1640, TRIzol and reverse transcription polymer-
ase chain reaction (RT-PCR) primers were purchased from
Invitrogen (Paisley, U.K.), fetal calf serum was from Biosera
(Ringmer, U.K.). Celltiter-Glo, Caspase–Glo8 and Caspase-
Glo 3/7 kits were from Promega (Southampton, U.K.).
Anti-cH2AX antibody was from Upstate Biotechnology
(Watford, U.K.) and anti-53BP1 and anti-BRD4 were from
Cambridge Biosciences (Cambridge, U.K.). Anti-p53 and
anti-c-MYC were from New England Biolabs (Hitchin,
U.K.). CompleteTM protease inhibitor cocktail (Roche, Bur-
gess Hill, U.K.) (ethylenediaminetetraacetic acid [EDTA]-
free) were from Roche (Burgess Hill, U.K.). Annexin
V/propidium iodide apoptosis detection kit was from BD
Biosciences (Oxford, U.K.). Protein A/G-Sepharose beads
were from GE Healthcare (Chalfont St Giles, U.K.).
Leukemia cell lines
Human Leukemia OCI-AML3 (AML-M4 subtype;
DNMT3A-R882; NPM1c-mutated; p53-wildtype) and
K562 (breakpoint cluster-Abelson murine leukemia viral
oncogene homolog 1, BCR-ABL) and Lymphoma RAJI
(Burkitt, MYC) cell lines were kind gifts from Dr. T. Gay-
mes (Kings College, London, U.K.) [9]. Cells were cul-
tured in RPMI 1640 supplemented with 10% fetal calf
serum, 100 mmol/l L-glutamine, penicillin (100 IU/mL),
streptomycin (100 lg/mL). The identity of the OCI-
AML3 cell line was confirmed by carrying out a restric-
tion-sensitive PCR assay for mutated DNMT3A at codon
R882 which this cell line harbors [10, 11].
Growth curves
OCI-AML3 cells were plated at a density of 80,000 cells
per well in a 24-well plate in 400 lL of cell culture med-
ium in the presence or absence of 0.25 lmol/L JQ1.
Phosphate-buffered saline (PBS) or JQ1 inactive enantio-
mer was added to control wells. Cells were counted every
24 h for 96 h in the presence of trypan blue (to deter-
mine cell viability) and the results recorded.
Cell viability assays
For cell lines cell viability was assessed using a WST-1
(4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulfonate) assay. 2 9 104 cells plated per
well in 96-well plates were incubated in the presence of
compound for the times indicated. Two to four hours
after the addition of WST-1, plates were read at 450 nm
in a Biotek Synergy plate reader (Biotek, Potton, U.K.)
and Gen5 version 1.08 software. The viability of untreated
cells was set as 100%, and viability in other groups was
calculated by comparing the optical density readings with
the control. All compounds were dissolved in dimethyl-
sulfoxide and stored at 20°C. Dilutions in PBS were
used for experiments.
Flow cytometry
Cells were treated with 0.25 lmol/L JQ1, 2 lmol/L Nutlin-
3 or a combination of both for 24 h and then stained with
anti-annexin V and propidium iodide using an apoptosis
detection kit (Promega, Southampton, U.K.). Labeled cells
were analyzed using a BD FACS Canto II six color (with
red and blue lasers) flow cytometer (BD, Oxford, U.K.).
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Immunolabeling of cH2AX and 53BP1
Cells were cytospun onto glass slides using a Shandon 3
cytospinner (Thermo Scientific, Northampton, U.K.) for
5 min at 650 rpm. Preparations were fixed in 4% parafor-
maldehyde for 15 min and then permeabilized with 0.2%
Triton X100 for 3 min. Mouse anti-γH2AX (1:500)
(Millipore, Watford, U.K.) and rabbit anti-53BP1 (1:1000;
Bethyl labs, Cambridge Biosciences, Cambridge, U.K.)
were applied for 1 h at room temperature. After washing
through PBS, cells were incubated in anti-rabbit Alexa
Fluor 488 (Life Technologies, Paisley, U.K.) (1:250) and
anti-mouse Alexa Flour 546 (1:250) for 30 min. After a
final wash through PBS, the slides were incubated in
DAPI (4′,6-diamidino-2-phenylindole) for 5 min and
then mounted in Citifluor anti-fade mounting medium
and viewed for fluorescence using a Leica DM 5000B
microscope fitted with a Leica DPC300FX digital camera
(Leica, London, U.K.).
Caspase 3/7 and caspase 8 assays
Activation of caspase 3/7 and caspase 8 was measured
using a Caspase-Glo 3/7 and Caspase-Glo 8 assays, respec-
tively. Cells were plated at a density of 20,000 cells per
well in black 96-well plates and treated with 0.5 lmol/L
JQ1 for various time points up to 48 h.
Preparation of cell extracts
Cells were isolated in a cooled centrifuge and washed
with 0.5 mL of ice-cold PBS containing 40 mmol/L
2-glycerophosphate and 2 mmol/L benzamidine. Pellets
were resuspended in 200 lL of ice-cold buffer A
(20 mmol/L Mops/KOH [pH 7.2], 10% [v/v] glycerol,
20 mmol/L sodium fluoride, 1 lmol/L microcystin LR,
75 mmol/L KCl, 2 mmol/L MgCl2, 2 mmol/L benzami-
dine, 2 mmol/L sodium orthovanadate and CompleteTM
protease inhibitor cocktail [Roche] [EDTA-free]) and
lysed by vortex mixing following the addition of 0.5%
Nonidet P40 and 0.5% sodium deoxycholate. Cell debris
was removed by centrifugation in a microfuge at
10,000 g for 5 min at 4°C, and the resultant superna-
tants were frozen in liquid nitrogen until use. For
immunoprecipitation experiments cells were pretreated
with 500 nmol/L daunorubicin and 400 nmol/L trichos-
tatin A (TSA) for 24 h to induce p53 expression and
hyper-acetylation prior to preparation of cell extracts.
Immunoprecipitation
Equal amounts of total protein extracts from OCI-AML3
or Hela cells were precleared with protein A/G-Sepharose
beads (GE Healthcare) at 4°C for 1 h. Supernatants were
immunoprecipitated for 2 h at 4°C with a BRD4-specific
antibody or with rabbit immunoglobulin as a negative
control. The protein–antibody complexes were pulled
down by adding protein A/G-Sepharose beads. Sample
pellets were then subjected to several washes in PBS. The
immunocomplexes were recovered from the protein A/G-
Sepharose beads by boiling the samples in electrophoresis
loading buffer. The immunocomplexes were analyzed by
Western blot using anti-p53 antibodies.
Western blotting
OCI-AML3 cells were treated with 0.5 lmol/L JQ1 for 24 h
and then harvested. Samples were then diluted in loading
buffer (with b-mercaptoethanol), boiled for 5 min, and
subjected to gel electrophoresis on 10% sodium dodecyl
sulfate-polyacrylamide gels (SDS-PAGE). A quantity of
36 lg of cell extract was loaded per lane. Proteins were
electrophoretically transferred onto PVDF for 1 h at
150 mA constant current. Immunolabeling was achieved by
blocking the gel with 5% milk for 1 h at room temperature
and then rotated overnight at 4°C with primary antibodies
diluted 1:2000 in Tris-buffered saline 0.1% Tween20. Sec-
ondary antibodies were used at a dilution of 1:20,000. Blots
were developed using a Vectastain ABC kit or a chemilumi-
nescent detection kit (Vector labs, Peterborough, U.K.).
Statistical analysis
All values are shown as mean  SEM from at least three
independent experiments (or a representative experiment
of three is shown) and considered significant if P < 0.05.
Significance between groups was calculated using
Student’s t-tests.
Results
JQ1 inhibits proliferation of the AML cell
line OCI-AML3 in a dose-dependent manner
The bromodomain inhibitor JQ1 has been reported to
inhibit the proliferation of many leukemia cells lines, par-
ticularly those containing MLL mutations [1]. We per-
formed experiments on OCI-AML3, a p53-wildtype AML
cell line that carries mutations in DNMT3A (R882C) and
NPM1c (exon-12) genes [12].
In preliminary experiments, a time–response curve to
analyze the effect of 1 lmol/L JQ1 on OCI-AML3 cell via-
bility was carried out using WST-1 assays. In subsequent
experiments, cells were analyzed at 72 h as this treatment
time caused a significant decrease in viability (Fig. 1A).
We found that JQ1 caused a dose-dependent decrease in
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cell viability with an IC50 of ~500 nmol/L (Fig. 1B). Con-
trol experiments using the inactive enantiomer (–)-JQ1 or
vehicle had no effect. For comparative purposes, K562
and Raji cells were used in additional experiments. The
p53-mutated K562 cell line responded poorly to the com-
pound as previously reported [1] with an IC50 of
>2 lmol/L whereas the Raji cell line was moderately sen-
sitive with an IC50 of ~1–2 lmol/L (Fig. 1B).
Growth curves confirmed that the decrease in cell via-
bility observed in JQ1-treated OCI-AML3 cells was due to
cell death (Fig. 1C). Flow cytometry analysis using propi-
dium iodide and annexin V staining confirmed that death
was by apoptosis (Fig. 1D).
JQ1 induces double-stranded DNA breaks
and pan-nuclear cH2AX staining
In order to determine the mechanism of action of JQ1,
we carried out experiments to look for DNA damage
responses. OCI-AML3 cells treated with 0.25 lmol/L JQ1
were immunolabeled for H2AX phosphorylation and
53BP1. JQ1 induced a robust increase in pan-nuclear
cH2AX staining indicative of an early apoptotic response
(Fig. 2A and B). This was accompanied by a significant
increase in 53BP1 foci (Fig. 2C) but not cH2AX foci.
Only 10% of cells with pan-nuclear cH2AX staining had
53BP1 foci. No increase in pan-nuclear cH2AX staining
was observed at 48 h although DAPI staining showed an
increase in pyknotic nuclei at this stage from 1.5  0.2%
to 3.2  0.17% (Fig. 2D, middle panel).
Time course experiments showed that induction of
pan-nuclear cH2AX occurred between 7 and 16 h after
JQ1 application. In contrast, treatment of cells with
1 lmol/L daunorubicin caused a marked increase in
cH2AX foci within 1 h (data not shown). In subsequent
experiments, cells were treated with 0.25 lmol/L JQ1 for
24 h and immunolabeled for cH2AX and proliferating cell
nuclear antigen (PCNA), a marker of S-phase cells. We
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Figure 1. JQ1 mediates cell death in OCI-AML3 cells. (A) OCI-AML3 cells were treated with 1 lmol/L JQ1 for 96 h and then cell viability was
measured using the WST-1 assay. (B) A time–response curve for 1 lmol/L JQ1 is shown. (C) Growth curves carried out over a 72-h period in the
presence of 0.25 or 0.5 lmol/L JQ1. (D) Cells were treated with 0.25 lmol/L JQ1, 0.5 lmol/L Nutlin-3 or a combination of both for 24 h and
stained for FACS analysis. Data are representative of at least three independent experiments performed in triplicate  SEM.
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found significant overlap between PCNA and immunola-
beling with ~90% of cH2AX-positive cells being double
labeled (Fig. 2D).
We also carried out experiments on cells treated with
0.25 lmol/L JQ1 and 10 lmol/L ATM inhibitor KU60019
simultaneously for 24 h which had no effect on the
induction of cH2AX. Likewise, cells simultaneously trea-
ted with JQ1 and caffeine (3 lmol/L) to inhibit the ATR-
CHK1 pathway showed no reduction in the number of
cells with cH2AX pan-nuclear labeling. Neither KU60019
nor caffeine alone stimulated the appearance of cH2AX.
Blocking of DNA-PK with 1 lmol/L NU7026 did,
however, prevent the nuclear accumulation of cH2AX in
JQ1-treated cells.
JQ1 induces apoptosis via a caspase 3/7 but
not caspase 8-dependent mechanism
Cells respond to DNA damage by activating signaling
cascades that cause cell cycle arrest to allow repair or
ControI JQ1
γH2AX
γ H2AX
Merge
DAPI
DAPIPCNA
A
D
B
C
Figure 2. JQ1 induces pan nuclear cH2AX labeling and 53BP1 foci in OCI-AML3 cells. (A) OCI-AML3 cells were treated with 1 lmol/L JQ1 for
24 h and then immunolabeled for cH2AX. (B) Graph showing cH2AX-positive cells (pan-nuclear staining). (C) Graph showing 53BP1 foci (counted
under 1009 magnification); Results shown are the mean of three separate experiments  SEM; *P < 0.05 as calculated by Student’s t-test
comparing control and JQ1-treated cells. (D) Cells immunolabeled for PCNA and cH2AX after treatment with 1 lmol/L JQ1.
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cause apoptosis to eliminate irreparably damaged cells. As
caspases are essential in cells for apoptosis, we carried out
experiments to determine if caspase activation occurs in
OCI-AML3 cells treated with JQ1. Cells were treated with
0.25 lmol/L JQ1 for 24 h and the luminescent signal
produced by caspase activation was measured using cas-
pase 3/7 and caspase 8 Glo kits (Promega). Figure 3A
shows that activation of caspase 3/7 occurs in JQ1-treated
cultures by 24 h. However, activation was not seen at 2
or 4 h time points. Caspase 3/7 activation was also
detected at 24 h in the Raji cell line but not in K562 cells
that are poorly responsive to JQ1.
Caspase 8, a caspase activated by the extrinsic apoptotic
pathway, was not activated by 24 h of JQ1 treatment but
was activated by BI2536 a polo-like kinase inhibitor, as
previously shown [13] (Fig. 3B).
Synergistic studies involving JQ1 and other
compounds
Caspase-dependent apoptosis is generally activated by
p53-dependent signal transduction pathways. Therefore,
we carried out experiments to test whether the p53 signal
transduction pathway could be implicated in JQ1-induced
apoptosis. We incubated cells with JQ1 together with
Nutlin-3, an HDM2 inhibitor. Compounds were applied
simultaneously to cells for 72 h. Nutlin-3 alone caused no
decrease in cell viability (over range 1–5 lmol/L). How-
ever, in combination with 0.25 lmol/L JQ1, there was a
marked decrease in cell viability that was significantly
greater than for JQ1 alone (Fig. 4A). Pre-treatment of the
cells with Nutlin-3 for 1 h before applying JQ1 produced
the same outcome.
The WST-1 assay is not able to distinguish between
effects on proliferation and cell death, so we hitherto
employed annexin V/propidium iodide flow cytometry to
directly measure apoptosis. Further experiments were
carried out to determine the role of HDACs in the mech-
anism of action of JQ1 as HDAC inhibitors have been
observed to activate p53 by acetylation [14]. We
employed three HDAC inhibitors, namely TSA, sodium
butyrate, and vorinostat, all of which exhibit activity
against class I and II HDACs [14]. We found that all
three HDAC inhibitors used at low concentrations
potentiated the effect of JQ1 in reducing cell viability
(Fig. 4B and C) and that for TSA this involved caspase
3/7-mediated apoptosis (Fig. 3A).
We carried out additional experiments with the anthra-
cycline daunorubicin, a chemotherapy drug used in stan-
dard AML treatment regimes. Again we found synergy
with this compound and JQ1 (Fig. 4D). Other com-
pounds tested including the ATM inhibitor KU60019,
cytosine arabinoside, polo-like kinase inhibitor BI2536,
p38 inhibitor SB203580 and mTOR inhibitor RAD001,
none of which showed evidence of synergy with JQ1 (data
not shown).
BRD4 interacts with p53 in OCI-AML3 cells
Our results indicate that the effects of JQ1 may be medi-
ated at least partly by the p53 pathway. Therefore, we
conducted experiments to investigate whether JQ1 had
any effect on p53 protein expression. OCI-AML3 cells
were incubated with 0.5 lmol/L JQ1 for 24 h and cell
extracts were then subjected to Western blotting. Fig-
ure 5A shows that JQ1 had no effect on endogenous p53
levels. Blots were probed with anti-c-MYC as a positive
A
B
Figure 3. JQ1 activates caspase 3/7 but not caspase 8. (A) OCI-
AML3, Raji, and K562 cells were plated at a density of 20,000 cells
per well in a 96-well plate, treated with 0.25 lmol/L JQ1 for 24 h,
then assayed for caspase3/7 activation in the presence or absence of
20 nmol/L TSA. (B) OCI-AML3 cells treated with 0.25 lmol/L JQ1
were assayed for caspase 8 activity (positive control experiment was
performed using 1 lmol/L polo-like kinase inhibitor BI-2536).
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control for JQ1 treatment. As expected, c-MYC levels
were downregulated.
We hypothesized that BRD4 might interact with acety-
lated p53 via bromodomain binding. OCI-AML3 and
Hela cells were exposed to daunorubicin and TSA in
order to induce p53 expression and hyper-acetylation.
Co-immunoprecipitation experiments were then per-
formed on the cell extracts using anti-BRD4 antibodies
and probing the Western blots with anti-p53. This
revealed that BRD4 associates with endogenous acetylated
p53 as hypothesized with no band seen in the rabbit
immunoglobulin control lane (Fig. 5B). In order to deter-
mine if this association occurred through an acetyl-lysine-
dependent mechanism, we repeated the co-immunopre-
cipitation experiment using protein extract from cells
treated with 1 lmol/L JQ1 in addition to daunorubicin
and TSA. We found that JQ1 exposure did not disrupt
the association between BRD4 and p53 (data not shown).
Similarly, JQ1 added to the extracted protein lysate at
concentrations up to 1 mmol/L failed to disrupt the asso-
ciation between BRD4 and p53. On the basis of these
observations, we conclude that BRD4 binds p53 in a
bromodomain-independent manner that is not affected
by JQ1. Rather, we propose that JQ1 prevents BRD4-
mediated recruitment of p53 to chromatin thereby pre-
venting normal activation of the DNA damage repair
response and leading instead to cellular apoptosis.
Discussion
Previous studies have shown that the BET bromodomain
inhibitor JQ1 causes cell death of both leukemia and
myeloma patient samples and of cell lines [1, 3, 4]. Here
we present data relating to the action of JQ1 on the
A B
C
D
Figure 4. The effect of JQ1 on OCI-AML cells is enhanced by Nutlin-3, HDAC inhibitors, and daunorubicin. Cells were plated at a density of
20,000 cells per well in a 96-well plate and then treated with: (A) 0.25 lmol/L JQ1 plus 0–2 lmol/L Nutlin-3; (B) 0.25 lmol/L JQ1 plus either
20 nmol/L TSA or 0.625 lmol/L Vorinostat (vorin) for 72 h; (C) 0.25 lmol/L JQ1 plus 0.5 mmol/L sodium butyrate; (D) 0.25 lmol/L JQ1 plus
0–50 nmol/L daunorubicin. Cell viability was assayed using the WST-1 assay and results shown are from three separate experiments performed in
triplicate  SEM.
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p53-wildtype OCI-AML3 leukemia cell line, which carries
mutations of the DNMT3A and NPM1 genes that are
known to occur frequently in AML. We show that
the OCI-AML3 cell line is sensitive to submicromolar
concentrations of JQ1. JQ1 induces a dose-dependent
decrease in cell viability, caspase3/7-mediated apoptosis,
and an increase in DNA damage. In addition, we show
synergy between JQ1 and daunorubicin, HDAC inhibitors
and the HDM2 inhibitor Nutlin-3 in causing apoptosis.
JQ1-mediated apoptosis is stimulated by caspase 3/7 acti-
vation but not caspase 8 activation indicating that the
intrinsic apoptotic pathway is involved.
JQ1 induces DNA double-stranded breaks (DSB) in
OCI-AML3 cells as monitored by the appearance of
53BP1 foci, a gene that is critical for the control of DSB
repair, and stimulates a massive upregulation in phos-
phorylated histone H2AX. Phosphorylation of H2AX at
serine 139 (cH2AX) is an early sign of DNA damage
induced by replication stalling. Upregulation takes at least
7 h and is maximal within 24 h. cH2AX is not detected
as discrete foci but rather as uniform pan nuclear stain-
ing. This pattern of cH2AX distribution has been
reported in previous studies [15, 16]. In both this study
and that of de Feraudy et al. [15], a correlation between
cH2AX and S-phase was observed.
The accumulation of pan nuclear cH2AX was not
affected by ATM or ATR inhibitors but was reduced by
DNA-PK inhibition. DNA-PK phosphorylates H2AX dur-
ing apoptotic fragmentation in mammalian cells with a
delayed time course relative to ionizing radiation [17].
Therefore, we conclude that in our cells cH2AX phos-
phorylation is induced by JQ1 in response to apoptotic
fragmentation. DNA-PK signaling of DNA damage is
probably mediated by p53 [18, 19].
Previous studies have demonstrated a clear role for
c-MYC in the mechanism of action of JQ1. c-MYC levels
are rapidly downregulated in many hematological cell
lines [3, 4] confirmed in our Western blotting experi-
ments on OCI-AML3 cells. Furthermore, CHIP experi-
ments reveal that BRD4 binds to the c-MYC promoter,
an action that is reversed by JQ1 [3, 4]. However, c-MYC
downregulation alone is not sufficient to induce apoptosis
as several cell lines (K562, Jurkat, and MDA MB-231) in
which JQ1 induces very little cell death show significant
downregulation of c-MYC transcripts [1, 20].
Our data suggest a role for p53 in the mechanism of
action of BRD4. Numerous studies including ours have
shown that BRD4 inhibition leads to cell cycle arrest,
senescence, p21 upregulation and apoptosis, all processes
mediated by p53 [21]. In addition, we show synergy
between JQ1 and the HDM2 inhibitor Nutlin-3, HDAC
inhibitors and the anthracycline daunorubicin. Nutlin-3
has been shown to rapidly activate p53 in cancer cells
with wildtype p53 [22, 23] by inhibiting the interaction
between HDM2 and p53, thus stabilizing p53. Likewise,
we show that HDAC inhibitors, compounds that main-
tain p53 in an active acetylated form [24], synergize with
JQ1. Acetylation of p53 is crucial for p53-mediated apop-
tosis [25] and also inhibits p53–HDM2 interactions [26,
27]. In addition, our results show that DNA-damaging
agents such as daunorubicin, a chemotherapy agent com-
monly used in leukemia treatment, also synergize with
JQ1 in OCI-AML3 cells. Daunorubicin causes p53 to bind
to DNA [28] providing additional support for a role for
p53 in JQ1-induced apoptosis.
Our Western blotting studies show that the effects of
JQ1 are not mediated by a direct effect of BRD4 inhibi-
tion on p53 protein levels. However, our immunoprecipi-
tation experiments show that p53 directly interacts with
BRD4 in both the OCI-AML3 and Hela cell lines con-
firming the recently published observations of Wu et al.
[29]. Further evidence for a role for p53 comes from gene
expression analysis of acute lymphoblastic leukemia cells
that revealed that genes involved in p53 stabilization are
upregulated in response to JQ1 [30]. We show that the
association of p53 with BRD4 is not inhibited by JQ1,
suggesting it does not occur via a bromodomain-
dependent mechanism. Indeed, it has very recently
been reported that the interaction of BRD4 and p53 is
modulated by two conserved regions, namely the phos-
phorylation-dependent interaction domain (PDID, that
encompasses bromodomain 2) and the basic residue-
enriched interaction domain (BID) [29]. Although the
A
B
Figure 5. (A) Brd4 interacts with p53 in a JQ1-independent manner.
Cells were treated with 0.5 lmol/L JQ1 for 24 h and then the
extracted protein was subjected to gel electrophoresis and Western
blotting for p53 and c-MYC (GAPDH was used as a loading
control). (B) Co-immunoprecipitation studies were performed by
immunoprecipitating the cell extracts for both Hela and OCI-AML3
cells with anti-BRD4 (or rabbit immunoglobulin as a negative
control), and then Western blotting with anti-p53.
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protein extracts used in our immunoprecipitation experi-
ments were hyper-acetylated by prior exposure to TSA,
we did not conclusively establish whether acetylation of
p53 facilitates its association with BRD4. However, our
observations clearly raise this possibility and are consis-
tent with other studies that show interaction between
purified BRD4 and acetylated p53 in vitro [29]. Other
bromodomain-containing proteins have also been shown
to interact with acetylated p53 including BRD7 [31] and
p300/CBP [32, 33]. BRD4 itself has been shown to bind
to acetylated NFjB [7]. As yet the effect of acetylation of
p53 on BRD4 interactions and gene transcription has not
been analyzed.
Interestingly, it has been shown that p53 can mediate
transcriptional repression of c-MYC. p53 is required for
c-MYC-dependent cell cycle arrest and differentiation but
not apoptosis [34], a finding in concert with the actions of
JQ1 where ectopic expression of c-MYC in hematological
cell lines confers significant resistance to JQ1-induced cell
cycle arrest and differentiation [1, 3] but cell death is not
affected [1]. Importantly, JQ1 appears to be particularly
potent against AML cells which usually lack p53 mutations
occurring in less than 10% of patients [35] compared with
around 50% for other human cancers [36].
In conclusion, this study suggests that inhibition of
BRD4 by JQ1 induces cell cycle arrest and/or apoptosis of
AML cells in a p53-mediated manner. We find that com-
pounds known to induce p53 activity such as daunorubi-
cin via DNA damage, Nutlin-3 via HDM2 inhibition, and
TSA via HDAC inhibition, all result in significant synergy
with JQ1 in OCI-AML3 cells, an AML cell line with intact
functional p53. We show that p53 binds BRD4 but that
this interaction is not disrupted by JQ1, implying that
binding is not mediated by either of the two bromodo-
mains. This is in agreement with the studies of Wu et al.
[29]. We hypothesize that BRD4 is normally responsible
for recruiting p53 to chromatin in response to DNA dam-
age leading to cell cycle arrest and that this process is
inhibited by JQ1 leading to cell death in a c-MYC-inde-
pendent manner. In the case of AML, where p53 is com-
monly intact, these findings suggest that BET
bromodomain inhibition could potentiate the activity of
other chemotherapeutic agents that are known to act via
p53 activation. Finally, we show that JQ1 is active against
the leukemic cell line OCI-AML3, which contains the
commonly recurring NPM1c mutation and the highly
adverse DNMT3A R882C mutation, confirming its prom-
ise as a novel therapy in AML.
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